Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

Mostrar otras versiones (1)

BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule Janus kinase [JAK] inhibitor that is being investigated for ulcerative colitis [UC]. We evaluated health-related quality of life [HRQoL] in tofacitinib UC Phase 3 studies. METHODS: Patients ≥ 18 years old in OCTAVE Induction 1 [N = 598] and...

Descripción completa

Detalles Bibliográficos
Autores principales: Panés, Julian, Vermeire, Séverine, Lindsay, James O, Sands, Bruce E, Su, Chinyu, Friedman, Gary, Zhang, Haiying, Yarlas, Aaron, Bayliss, Martha, Maher, Stephen, Cappelleri, Joseph C, Bushmakin, Andrew G, Rubin, David T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881763/
https://www.ncbi.nlm.nih.gov/pubmed/29028981
http://dx.doi.org/10.1093/ecco-jcc/jjx133
Mostrar todas las versiones(2)

Ejemplares similares